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Introduction
Cholangiocarcinoma are malignant tumors that derive from bile duct epithelium and are classified anatomically into intra-and extra-hepatic cholangiocarcinoma. The incidence and the mortality rates of cholangiocarcinoma are increasing worldwide [1] . At present, complete resection is the only way to cure this disease, but at the time of diagnoses more than 60% of patients have occult metastases or an advanced local disease which preclude any curative resection. Conventional anticancer treatments, such as chemotherapy or radiotherapy have minimal impact on patients survival with unresectable tumor [2] [3] [4] [5] . Up to now, the factors responsible for this relative unresponsiveness have not been clearly understood. In general, the efficacy of conventional anticancer therapies is strongly dependent on their ability to initiate programmed cell death (apoptosis) in cancer cells [6] [7] [8] . Therefore, cancer cells that have evolved ways to circumvent apoptosis become resistant, providing an obstacle to effective treatments [9, 10] .
Previous researchers have shown that zoledronic acid (ZOL), third generation of biphosphonates (BPs), exerts powerful antitumoral activity [11] in several human neoplasms [11] such as human myeloma [12] , breast [13] and prostate [14, 15] cancers. BPs are currently the most important class of inhibitors of osteoclast-mediated bone resorption and are used extensively for the treatment of skeletal diseases, such as Paget's disease, postmenopausal osteoporosis, and tumor-induced osteolysis [16, 17] . The antiproliferative effect of pamidronate in human and rat osteosarcoma cells has recently been demonstrated in vitro [18, 19] . BPs can be divided into two distinct pharmacological classes based on their molecular mechanisms of action [20] . Non-nitrogencontaining BPs, such as clodronate and etidronate, are metabolized intracellularly as cytotoxic analogues of ATP and thus inhibit osteoclast activity [21] . In contrast, the newer nitrogen-
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A c c e p t e d M a n u s c r i p t 4 containing BPs such as alendronate, residronate, pamidronate, and ZOL inhibit cell proliferation and induce apoptosis in osteoclasts [22] by inhibiting farnesyl-PP-synthase of the mevalonate synthesis, a biosynthetic pathway responsible for the production of cholesterol and isoprenoid lipids, particularly farnesyl-and geranylpyrophosphates. These are required for the posttranslational modification (prenylation) of small GTP proteins (such as Rho, Ras, Rac) that play crucial roles in signaling pathways controlling cell growth. The anti-proliferative effect of ZOL was described in several tumor cell lines and it was likely due to cell cycle distribution change by accumulating and arresting cells in the S-phase [23] [24] [25] [26] [27] . This arrest was coupled to changing levels of cyclins and cell cycle regulators, and the S-phase arrest was associated with typical (caspase-dependent) [25, 27, 28] or atypical (caspase-independent) apoptotic pathway. To date, however, the detailed molecular mechanism of cell cycle arrest involved remains not fully understood.
Since most of patients with cholangiocarcinoma present at diagnoses with unresectable disease or the occurrence, in this cancer, of high-rate of post-resection relapse, the current adjuvant or palliative option is of limited benefit. It is mandatory, therefore, to evaluate new potential anticancer drugs. ZOL, due to its mechanism of action so far highlighted, could represent a reliable chemotherapeutic agent able to sensitize cells to cytotoxic agents and/or radiations.
Here we investigated, for the first time on two cholangiocarcinoma cell lines, the role of ZOL on cell morphology, proliferation, cycle phases, and apoptosis to regard its potential use in cholangiocarcinoma therapy.
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Methods and Materials

Reagents
Zoledronic acid (ZOL, ZOMETA®, Novartis Europharm, UK ) and gemcitabine (GEM, GEMZAR®, Eli Lilly, Italy) were kindly provided by Drs. Vittorio Rizzoli and Maria Cristina Baroni, Dipartimento di Medicina Interna e Scienze Biomediche, Università degli Studi di Parma. ZOL was dissolved in phosphate buffer saline (PBS) as a 5 mM stock solution while GEM as 100mM stock solution and both stored at -20°C . RPMI 1640 medium, staurosporine, geranylgeraniol (GGOH), pamidronate, clodronate, and phosphorylated histone H3 (pHH3, 8656-R), were purchased from Sigma-Aldrich (St. Louis, MO, USA), and fetal bovine serum (FBS) from Gibco-BRL (Grand Island, NY, USA). Antibodies against Bcl-xL (H-5), Bax (P-19), TP53
(DO-1), Rap1A (SC-1482, unprenylated form) were obtained from Santa Cruz Biotechnology (Santa Cruz, Temecula, CA, USA). Monoclonal antibody against HSP27 (G3.1) was from StressGene (Victoria, BC Canada); caspase-3, PARP, cyclin A, cyclin B1, cyclin D1, pRb1, Rb, and p27 antibodies were from Cell Signaling Technologies (Beverly, MA, USA); monoclonal anti-actin (AC-40) antibody was from Sigma Aldrich. HRP-conjugated secondary antibodies (Pierce, Rockford, IL, USA) and the enhanced chemiluminescence system (ECL) were from Millipore (Millipore Co, Billerica, MA, USA). Reagents for electrophoresis and blotting analysis were obtained from BIO-RAD Laboratories (Richmond, CA, USA). M a n u s c r i p t 6 
Cell culture
The cholangiocarcinoma cell lines EGI-1 and TFK-1 were obtained from the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, GERMANY) and maintained in RPMI-1640 medium, containing antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin) and supplemented with 10% FCS and with 2 mmol/L glutamine. Cultures were kept in an incubator at 37°C in a water-saturated 5% CO 2 atmosphere in air. Routine sub-cultivations were carried out every week. Cell morphology was assessed on May-Grünwald stained cells.
MTT assay
Viability of EGI-1 and TFK-1 cells was evaluated by [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] (MTT) (Sigma-Aldrich) assay. 5000 cells/well were seeded into 96-well plates and left to adhere overnight. The cells were then incubated for 3 days in the absence or in the presence of 1 to 1000µM ZOL. Then 100 µl of 1 mg/ml MTT were added for 1 h. After removal of the MTT, cells were treated with 100 µl DMSO and formazan product was solved.
The absorbance was determined at 595 nm in a multiwell plate reader (BIO-RAD, Microplate
Reader 555). Drug-induced proliferation changes were calculated as percentage of cell growth inhibition using the formula: (1-extinction of treated sample x 100) / (extinction of control sample). The half-maximal inhibition constant (IC 50 ) was determined using the nonlinear regression program CalcuSyn (Biosoft, Cambridge, UK).
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Clonogenic assay
Colony formation was determined by seeding cells into a six-well culture plates at a density of 50 cells/cm 2 well and left to adhere overnight. The cells were then incubated in the absence or in the presence of 2-32µM ZOL. After 10 day-incubation, the wells were washed twice with PBS, and fixed with 1% formaldehyde. They were then stained with 0.1% crystal violet. The colony is defined to consist of at least 40-50 cells. For evaluation of cell growth, colonies were examined under a light microscope.
Western blotting
Total proteins were extracted by lysing the cells with a buffer containing 50mM Tris-HCL, pH 7.4, 150mM NaCl, 5mM MgCl 2 , 0.5mM EDTA, 0.1% SDS and protease inhibitor cocktail followed by ultracentrifugation at 13,000 rpm for 10 min. Protein concentration was determined using a protein assay from BIO-RAD according to the manufacturer's protocol, using BSA as standard. Proteins (50µg) were resolved by SDS/PAGE (12%) and blotted onto PVDF membranes (Millipore). Immunodetection was carried out in 50mM Tris-HCl, pH 7.4, 150mM
NaCl, 0.1% Tween 20, 5% non-fat dry milk, followed by HRP conjugated secondary antibodies at 1:20000 dilution. Detection was performed using an ECL kit.
Flow cytometric cell cycle and morphological analysis
Cholangiocarcinoma cells were incubated with 10 and 50µM ZOL for 72 h. For the cell cycle assay EGI-1 and TFK-1 cells were harvested and subjected centrifugation, 5x10 5 
Growth inhibitory effects
In order to test the effect of ZOL on cholangiocarcinoma cell growth, EGI-1 and TFK-1 cell lines
were treated with increasing concentration of ZOL (1 to 1000µM) for 72h, followed by an MTT assay (see Material and Methods section). As revealed in Figure 
Rescue by GGOH of morphological and proliferation changes induced by ZOL
Besides the significant inhibition of proliferation induced by ZOL at relatively high Figure 2C ). This ability of GGOH to alleviate/rescue ZOL toxicity could be ascribed to cell replenishing of substrates for protein prenylation. 
Loss of clonogenic survival
Expression of putative phase markers and cell cycle regulators
We then examined the mechanisms of ZOL induced S-phase arrest by focusing on the expression level of phase-specific cyclins and the cell cycle regulators such as tumor suppressor pRb and M a n u s c r i p t 12 p27 KIP1 . Modified expression and/or phosphorylation of these molecules are indicative of which checkpoints may be involved. Checkpoints are important sensors that ensure the proper sequence of cell cycle events allowing cells to repair DNA damage. There are at least three checkpoints at G1/S, S and G2/M phases that can allow DNA repair and promote cell death in unrepaired cells.
The first checkpoint at G1/S is often compromised in malignant cells due to deletion or loss of function of TP53, guardian of the genome, and/or mutation of pRb, main regulator of the cell cycle. As shown in Figure 5 , while we confirmed the absence of TP53 in TFK-1 cells as known from literature data, its overexpression in EGI-1 cells is likely to be ineffective due to the presence of one deleterious transition mutation (G>A, R273H) in the DNA binding domain that prevents its binding to DNA [29] . pRb protein hinders the cell from replicating damaged DNA by preventing its progression along the cell cycle through G1 into S. In the hypophosphorylated state, pRb protein is active and carries out its role as tumor suppressor by inhibiting cell cycle progression. Phosphorylation inactivates pRb. As shown in Figure 5 , We then examined the cyclins, putative markers of cell cycle phases and regulatory subunits of the cyclin-dependent kinases (cdks), whose levels peak the specific stages of the cell cycle. The first cyclin level examined was cyclin D1, which is maximally expressed in mid-to-late G1 phase and its kinase activity, elicited by binding with cdk4 (predominantly cyclin D1/cdk4 complex), is up-regulated in cancer cells [30] . As shown in Figure 6 , treating cells for up to 72 h with 10-100 , which shares with pRb and p27 a regulatory role at G1/S checkpoint, is frequently mutated or deleted in a wide variety of tumors, in particular in bile duct cancers, and not expressed in the cholangiocarcinoma cell lines used in this work [31, 32] . In several human malignancies, the loss, mutation or silencing of the gene encoding the CDK4 inhibitor p16 INK4a hyperactivates the kinase activity of CDK4 [33] [34] [35] . Next, cyclin A expression is important for progression through the S phase and G2/M transition [36] . Cyclin A, in contrast to cyclin D1, showed significant increases in both cell lines following cell exposed to ZOL and thus indicating a slow-down and/or an arrest in the S-phase.
Moreover, cyclin B1, in complex with cdk1, functions as an M-phase kinase [37] . No changes of cyclin B1 level were observed in both cell lines except a distinct drop at 50µM ZOL in EGI-1 cells. Finally, we analyzed the phospho-histone H3, a marker of cromatin condensation. The
Western blotting analysis indicated that ZOL increases the level of this M-phase marker. This increment was in agreement with the increased level of cyclins A.
These findings on the significant changes in the levels of specific cell cycle cyclins and inhibitors confirm the results observed with cell-cycle analysis and further indicate a ZOL interference with the cell cycle progression machinery at the putative S-phase check point.
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Apoptosis assessment
As shown in Figure 4 , in both cholangiocarcinoma cell lines, ZOL treatment did not induce any apoptotic sub-G1 peak. In order to confirm the absence of apoptotic death, we examined the morphological and biochemical features of apoptosis. The cells were stained with Hoechst 33342 and propidium iodide. Condensed chromatin or apoptotic cells were rarely seen in all the cell populations studied: only 8-12% of control cells and of tested cells treated with the drug up to 25µM were homogeneously and intensively stained by propidium iodide indicating cell death.
None evident characteristics of apoptosis (such as cell shrinkage, apoptotic bodies, cytoplasmic blebs, chromatin collapse into patches and dense spheres) were observed. Only when EGI-1 cells were treated with 50µM, approximately 10% of cells showed some apoptotic characteristics (not shown).
We then investigated the occurrence of apoptosis by biochemical criteria such as activation of caspases or presence of cleavage products of their substrates. Figure 6A shows that none effect on caspase-3 activation occurred after cells exposure to ZOL. Moreover, the drug did not induce cleavage of PARP, a key enzyme in the apoptotic cascade and substrate of active caspase-3.
To investigate if the cell-death resistance is specific to zoledronic acid, we evaluate the effect of staurosporine, gemcitabine and nitrogen (pamidronate) and a non-nitrogen (clodronate)
containing bisphosphonate on caspase-3 and PARP activation. Experiments using the abovementioned drugs indicated that staurosporine on EGI-1 cells and gemcitabine on both cell lines were able to induce caspase-3 and PARP activation. In contrast and similarly to ZOL, pamidronate and clodronate did not activate caspase-3 nor PARP ( Figure 6B ).
The analysis of the expression of anti-versus pro-apoptotic proteins indicated that untreated TFK-1 cells markedly express the anti-apoptotic Bcl-xL and at greater extent the pro-apoptotic A c c e p t e d M a n u s c r i p t
15
Bax protein, accordingly to literature data [38, 39] . As shown in Figure 6C , in TFK-1 cells ZOL treatment significantly affected the balance of anti-apoptotic versus pro-apoptotic proteins; it is also interesting to note the marked decrease of Bax coupled to the increasing concentrations of ZOL. Moreover, in EGI-1 cells ZOL treatment did not affect the ratio of Bcl-xL/Bax, already shifted versus the anti-apoptotic Bcl-xL protein.
We then addressed the question whether the observed apoptosis resistance of S-phase arrested cells were associated to high expression of HSP27. HSP27, a powerful chaperone, is a stress protein induced in response to a variety of insults including oncogenic transformation and chemotherapic agents. Its expression allows/helps tumor cells to survive otherwise lethal conditions by counteracting at multiple control points of the apoptotic pathway and therefore increasing the tumorigenic potential of cancer cells [40] . As shown in Figure 6C , constitutive expression of HSP27 was clearly evident in untreated TFK-1 cells; however, ZOL treatment did not affect its expression. In contrast, in EGI-1 cells HSP27 was not present and ZOL treatment did not induce its expression.
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Discussion
Despite recent improvements in surgery and the development of different regimens of multidrug chemotherapy over the past 25 years, survival of patients suffering from cholangiocarcinoma remains around 5 to 20% after 5 years [41, 42] . The poor prognosis of cholangiocarcinoma [2] warrants new therapeutic strategies to improve the overall rate of survival, especially in high-risk subgroups.
In the present study, we examined the commonly used biphosphonate molecule ZOL, because of its high biological activity in inducing inhibition of proliferation and apoptosis in several cancer cell lines [20] . We here reported that ZOL, the most potent nitrogen containing BP, causes The ability to form a colony from a single cell, may be seen as a surrogate of the invasive ability of the tumor cell [43] . Interestingly, in cholangiocarcinoma cells this ability is markedly impaired at 8µM ZOL, a concentration 2-4 fold lower than those seen in the MTT assay. It should be noted that cells, exposed up to IC 50 ZOL for 72h, following drug removal later on resume their growth thus indicating the reversibility of the inhibition. In our opinion, this property of ZOL suggests its induce G1/S arrest, as already seen in other tumor cells [26, 46] . It determines an arrest of cells in the S-phase without an accumulation of cells in the G2-phase and absence of apoptosis induction.
Several studies have described induction of apoptosis (caspase-dependent and -independent) by the administration of ZOL to cancer cells. For example, in breast cancer ZOL decreased the cell growth in a dose-dependent manner, this effect being ascribed to the concomitant BP-induced increase in cell apoptosis [47] . Similarly, it was reported that ZOL was able to induce apoptotic death in several pancreatic cells achieving 35-90% of apoptotic cells in the treated groups.
Independently of the TP53 and pRb status, in osteosarcoma cells, it was recently described a ZOL induction of atypical apoptosis independent of caspase activation and involving the mitochondrial pathway, in particular the translocation to the nucleus of the apoptosis-inducing factor (AIF) [27] . Our data support the notion that ZOL could inhibit cholangiocarcinoma cell proliferation by inducing cell accumulation/arrest in the S-phase but without inducing apoptosis.
We have found that, subsequent to ZOL treatment both TFK-1 and EGI-1 cells are prevented to activate the apoptotic pathway as shown by the lack of sub-G1 peak, and the absence of caspase 3 cleaved fragment. This outcome was confirmed by lack of morphological features of apoptosis.
This lack of apoptosis was not specific to ZOL treatment since similar results were obtained by using pamidronate (N-BP) or clodronate (BP). It worth to note that these cells are quite resistant to cell death as shown by moderate caspase-3 activation observed in the presence of a high concentration of staurosporine (a classical inducer of apoptosis in several cells). Interestingly, in staurosporine-exposed PC-3 cells the overexpression of anti-apoptotic protein Bcl-xL was found to be associated with resistance because of abrogation of cytochrome c release to the cytosol [48] .
Discrepant observations about the ability of biphosphonates to induce apoptosis was reported by
Lee et al. [49] . These authors showed that reduction in prostate cell growth was mainly mediated by cell cycle prolongation. Other two papers related to breast and lung cancer [50, 51] proteins, such as Bcl-2 proteins, within the biliary tree could play a key role in the development of cholangiocarcinoma [38, 39] . A few years ago it was reported that the enhanced Bcl-2 expression alters the threshold for apoptosis in a cholangiocarcinoma cell line [52] . Moreover, Bcl-2 over-expression could protect myeloma cells against ZOL-induced apoptosis but not against cytostasis [53] . In agreement with this report, our results show that Bcl-xL, an antiapoptotic member of the Bcl-2 family proteins, is significantly expressed in both cholangiocarcinoma cell lines, while the pro-apoptotic Bax protein is largely expressed only in TFK-1 cells. ZOL treatment reverted the ratio between pro-apoptotic Bax versus anti-apoptotic Bcl-xL in TFK-1 cells, meanwhile in EGI-1 cells this ratio, already shifted versus the antiapoptotic component, was unaffected by the drug.
Our results support the plausible anti-apoptotic role of the Bcl-xL protein to contrast the cytotoxic effect of ZOL as observed by other authors [38] . As already indicated above, Bcl-xL overexpression is one of the mediator of resistance to staurosporine-induced apoptosis [48] .
Recently, it was shown that Bcl-xL overexpression protects from apoptosis induced by HMGCoA reductase inhibitors (simvastatin) in murine tubular cell line [54] . Moreover, antisense BclxL down-regulation has been reported to induce apoptosis in colorectal cancer cells [55] . Taken together, these reports and our results suggest that the expression of Bcl-xL protein might prevent cellular apoptosis, and confirm, at least in vitro, the resistance of TFK-1 and EGI-1 cells to the M a n u s c r i p t 20 apoptosis-inducing effects of ZOL. An additional mechanism that emerges from this study and might explain the higher resistance to ZOL exhibited by TFK-1 cells, in comparison to EGI-1 cells (IC 50 = 37 vs 17), could be linked to the constitutive expression of the antiapoptotic HSP27
protein. This remark is suggested by the known role of HSP27 in conferring chemotherapy resistance, in inhibiting apoptotic cell death, and facilitating tumor progression [56, 57] . Our previous results suggest that HSP27 could be also a prognostic factor in cholangiocarcinoma [58] In conclusion, our study provides the first evidence that ZOL elicits a direct inhibitory action on the proliferation of cholangiocarcinoma cells. The cell-cycle alteration induced by ZOL, i.è. cell accumulation/arrest in S-phase, was confirmed by changes in the level of cyclins D1 and A, and of regulators p27 KIP1 and pRb. ZOL therefore, could represent a reliable chemotherapeutic agent able to sensitize cells to cytotoxic agents and/or radiations.
Our data indicate that a dose of 10-50 µM ZOL is required for a significant cell cycle arrest in cholangiocarcinoma cells. This range of concentrations, however, may preclude ZOL to be used as monotherapy in cholangiocarcinoma, thus making mandatory the need to investigate differently active molecules to associate with ZOL, in order to obtain a synergistic therapeutic improvement and minimizing, in the same time, the side effects. 
